Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.

Damiani, Giovanni; Pacifico, Alessia; Bragazzi, Nicola L; Malagoli, Piergiorgio

Damiani, Giovanni; Pacifico, Alessia; Bragazzi, Nicola L; Malagoli, Piergiorgio.

Affiliation

Damiani G; Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
Pacifico A; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Bragazzi NL; Phototherapy Unit, San Gallicano Dermatological Hospital, Rome, Italy.
Malagoli P; Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, Canada.

Dermatol Ther ; 33(5): e13475, 2020 09.

Article in En | MEDLINE | ID: mdl-32356577

Subject(s)

Biological Products/adverse effects; COVID-19/etiology; Intensive Care Units; Psoriasis/drug therapy; SARS-CoV-2; Adult; Aged; COVID-19/mortality; Case-Control Studies; Cohort Studies; Female; Hospitalization; Humans; Male; Middle Aged; Risk

Key words

COVID-19; SARS-CoV-2; bilateral interstitial pneumonia; biologics; pandemic; psoriasis; psoriatic arthritis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Biological Products / SARS-CoV-2 / COVID-19 / Intensive Care Units Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Dermatol Ther Journal subject: DERMATOLOGIA Year: 2020 Type: Article Affiliation country: Italy

Fulltext

XML

PubMed Links

Search on Google